Corey Anderson, MD
Family Medicine · Mesa, AZNPI 1720050727
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,160 of the $8,138 with a category attached, or 63.4%. 6 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 44.2% of the total. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $166.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$4K
- Boehringer Ingelheim International GmbH$1K
- Pfizer$1K
- Merck$1K
- Shionogi Inc$688
- Abbott$26
Across 4,399 payments — averaging $4913.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$7.4M
- Pfizer$3M
- Biontech SE$1.7M
- Emergent Biosolutions Inc.$1.3M
- Merck$1.3M
- Valneva Austria GmbH$1.1M
- plus $5.7M from 30 others
What the payments were for
- Consulting fees$1,22515%
- Travel & lodging$5,16063%
- Food & beverage$1,73321%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 21 | $3,594 |
| Boehringer Ingelheim International GmbH | 11 | $1,336 |
| Pfizer | 6 | $1,270 |
| Merck | 1 | $1,225 |
| Shionogi Inc | 8 | $688 |
| Abbott | 2 | $26 |
How this compares
$8,138 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $277 |
| Azithromycin | 65 | $153 |
| Cephalexin | 25 | $120 |
| Prednisone | 75 | $115 |
| Tizanidine Hcl | 27 | $93 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $58 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $39 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $39 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Mesa
- Suzanne BentzMesa$174K
- Karen Acevedo MogharbelMesa$59K
- James GunnMesa$17K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.